<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-597-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROCORALAN 5 MG F-C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IVABRADINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        149.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SERVIER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01EB17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:417.8pt;margin-top:12.9pt;width:31.35pt;
 height:13.35pt;z-index:-251659776;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="627,267" o:allowincell="f"
 path="m,266hhl626,266,626,,,,,266xe" fillcolor="#f8f9fa" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><!--[if !vml]--><img width="42" height="18" src="file:///C:/Users/AHAN_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[endif]-->Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fration <strong>&le; 35% </strong>who are in sinus rhythm with resting heart rate &ge; 70 bpm, and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta &ndash;blocker use</p><p>&nbsp;</p><p>&nbsp;</p><p><u>About chronic heart failure :</u></p><p>Chronic heart failure is a heart disease which happens when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.</p><p>&nbsp;</p><p><u>How does Procoralan work?</u></p><p>Procoralan mainly works by reducing the heart rate by a few beats per minute. As elevated heart rate adversely affects the heart functioning and vital prognosis in patients with chronic heart failure, the specific heart rate lowering action of ivabradine helps to improve the heart functioning and vital prognosis in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><!--[if !supportLists]--><strong>a.&nbsp; </strong><!--[endif]--><strong>Do not take Procoralan</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 6);</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if your resting heart rate before treatment is too slow (below 70 beats per minute);</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are suffering from cardiogenic shock (a heart condition treated in hospital);</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from a heart rhythm disorder;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are having a heart attack;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from very low blood pressure;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion);</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have heart failure which has recently become worse;</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if your heart beat is exclusively imposed by your pacemaker;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from severe liver problems;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are already taking medicines for the treatment of fungal infections (such as ketoconazole, itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin or erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) or nefazodone (medicine to treat depression) or diltiazem, verapamil (used for high blood pressure or angina pectoris);</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are a woman able to have children and not using reliable contraception;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are pregnant or trying to become pregnant;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are breast-feeding.</p><p>&nbsp;</p><p><!--[if !supportLists]-->b.&nbsp; <!--[endif]-->Take special care with Procoralan</p><p>Talk to your doctor, health care provider or pharmacist before taking Procoralan</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of electrocardiogram (ECG) called &lsquo;long QT syndrome&rsquo;,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have had a recent stroke (cerebral attack),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from mild to moderate low blood pressure,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from severe heart failure or heart failure with abnormality of ECG called &lsquo;bundle branch block&rsquo;,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from chronic eye retinal disease,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from moderate liver problems,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you suffer from severe renal problems.</p><p>If any of the above applies to you, talk straight away to your doctor or health care provider before or while taking Procoralan.</p><p>&nbsp;</p><p>Children</p><p>Procoralan is not intended for use in children and adolescents younger than 18 years.</p><p>&nbsp;</p><p><!--[if !supportLists]-->c.&nbsp; <!--[endif]-->Taking other medicines, herbal or dietary supplements</p><p>Tell your doctor, health care provider or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Make sure to tell your doctor or health care provider if you are taking any of the following medicines, as a dose adjustment of Procoralan or monitoring should be required:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fluconazole (an antifungal medicine)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rifampicin (an antibiotic)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->barbiturates (for difficult sleeping or epilepsy)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->phenytoin (for epilepsy)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Hypericum perforatum </em>or St John&rsquo;s Wort (herbal treatment for depression)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->QT prolonging medicines to treat either heart rhythm disorders or other conditions :</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bepridil (to treat angina pectoris)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->certain types of medicines to treat anxiety, schizophrenia or other psychoses (such as pimozide, ziprasidone, sertindole)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->anti-malarial medicines (such as mefloquine or halofantrine)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->intravenous erythromycin (an antibiotic)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pentamidine (an antiparasitic medicine)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cisapride (against the gastro-oesophageal reflux)</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure).</p><p>&nbsp;</p><p><!--[if !supportLists]-->d.&nbsp; <!--[endif]-->Taking Procoralan with food and drink</p><p>Avoid grapefruit juice during treatment with Procoralan.</p><p>&nbsp;</p><p><!--[if !supportLists]-->e.&nbsp; <!--[endif]-->Pregnancy and breast-feeding</p><p>Do not take Procoralan if you are pregnant or are planning to have a baby (see &ldquo;Do not take Procoralan&rdquo;).</p><p>If you are pregnant and have taken Procoralan, talk to your doctor or health care provider.</p><p>Do not take Procoralan if you are able to become pregnant unless you use reliable contraceptive measures (see &ldquo;Do not take Procoralan&rdquo;).</p><p>Do not take Procoralan if you are breast-feeding (see &ldquo;Do not take Procoralan&rdquo;). Talk to your doctor or health care provider if you are breast-feeding or intending to breast-feed as breastfeeding should be discontinued if you take Procoralan.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, health care provider or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><!--[if !supportLists]-->f.&nbsp; <!--[endif]-->Driving and using machines</p><p>Procoralan may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see &ldquo;Possible side effects&rdquo;). If this happens to you, be careful when driving or using machines at times when there could be sudden changes in light intensity, especially when driving at night.</p><p>&nbsp;</p><p><!--[if !supportLists]-->g.&nbsp; <!--[endif]-->Important information about some of the ingredients of Procoralan</p><p>Procoralan contains lactose.</p><p>If you have been told by your doctor, health care provider that you have an intolerance to some sugars, contact your doctor, health care provider before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor, health care provider or pharmacist has told you. Check with your doctor, health care provider or pharmacist if you are not sure.</p><p>Procoralan should be taken during meals.</p><p>&nbsp;</p><p>The usual recommended starting dose is one tablet of Procoralan 5 mg twice daily increasing if necessary to one tablet of Procoralan 7.5 mg twice daily. Your doctor or health care provider will decide the right dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if you are elderly), your doctor or health care provider may prescribe half the dose i.e., one half 5 mg tablet of Procoralan 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.</p><p>&nbsp;</p><p><!--[if !supportLists]-->a.&nbsp; <!--[endif]-->If you take more Procoralan than you should:</p><p>A large dose of Procoralan could make you feel breathless or tired because your heart slows down too much. If this happens, contact your doctor or health care provider immediately.</p><p>&nbsp;</p><p><!--[if !supportLists]-->b.&nbsp; <!--[endif]-->If you forget to take Procoralan:</p><p>If you forget to take a dose of Procoralan, take the next dose at the usual time. Do not take a double dose to make up for the forgotten dose.</p><p>The calendar printed on the blister containing the tablets should help you remember when you last took a tablet of Procoralan.</p><p>&nbsp;</p><p><!--[if !supportLists]-->c.&nbsp; <!--[endif]-->If you stop taking Procoralan:</p><p>As the treatment for chronic heart failure is usually life-long, you should discuss with your doctor or health care provider before stopping this medicinal product.</p><p>If you think that the effect of Procoralan is too strong or too weak, talk to your doctor, health care provider or pharmacist.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The frequency of possible side effects listed below is defined using the following convention: very common: may affect more than 1 in 10 people</p><p>common: may affect up to 1 in 10 people uncommon: may affect up to 1 in 100 people rare: may affect up to 1 in 1,000 people</p><p>very rare: may affect up to 1 in 10,000 people</p><p>not known: frequency cannot be estimated from the available data</p><p>&nbsp;</p><p>The most common adverse reactions with this medicine are dose dependent and related to its mode of action:</p><p>&nbsp;</p><p><em>Very common:</em></p><p>Luminous visual phenomena (brief moments of increased brightness, most often caused by sudden changes in light intensity). They can also be described as a halo, coloured flashes, image decomposition or multiple images. They generally occur within the first two months of treatment after which they may occur repeatedly and resolve during or after treatment</p><p>&nbsp;</p><p><em>Common:</em></p><p>Modification in the heart functioning (the symptoms are a slowing down of the heart rate). They particularly occur within the first 2 to 3 months of treatment initiation.</p><p>&nbsp;</p><p>Other side effects have also been reported:</p><p>&nbsp;</p><p><em>Common:</em></p><p>Irregular &nbsp;rapid &nbsp;contraction &nbsp;of &nbsp;the &nbsp;heart, &nbsp;abnormal &nbsp;perception &nbsp;of &nbsp;heartbeat, &nbsp;uncontrolled &nbsp;blood pressure, headache, dizziness and blurred vision (cloudy vision).</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle cramps, changes in laboratory parameters : high blood levels of uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG heart tracing, double vision, impaired vision.</p><p>&nbsp;</p><p><em>Rare:</em></p><p>Urticaria, itching, skin reddening, feeling unwell.</p><p>&nbsp;</p><p><em>Very rare:</em></p><p>Irregular heart beats.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, health care provider or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store below 30&deg;C, in the original carton.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is ivabradine (as hydrochloride).</p><p>Procoralan &nbsp;5 mg: &nbsp;one &nbsp;film-coated &nbsp;tablet &nbsp;contains &nbsp;5 mg &nbsp;ivabradine &nbsp;(equivalent &nbsp;to &nbsp;5.390 mg ivabradine as hydrochloride).</p><p>Procoralan 7.5 mg: one film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients in the tablet core are: lactose monohydrate, magnesium stearate (E 470 B), maize starch, maltodextrin, colloidal anhydrous silica (E 551), and in the tablet coating: hypromellose (E 464), titanium dioxide (E 171), macrogol 6000, glycerol (E 422), magnesium stearate (E 470 B), yellow iron oxide (E 172), red iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Procoralan 5 mg tablets are salmon-coloured, oblong film-coated tablets scored on both sides, engraved with “5” on one face and        on the other. 
Procoralan 7.5 mg tablets are salmon-coloured, triangular, film-coated tablets engraved with “7.5” on one face and  on the other.

The tablets are available in calendar packs (Aluminium/PVC blisters) of 14, 28, 56, 84, 98, 100 or 112 tablets.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder:</u> Les Laboratoires Servier</p><p>50 rue Carnot</p><p>92284 Suresnes cedex France</p><p>&nbsp;</p><p><u>Manufacturer:</u></p><p>Servier (Ireland) Industries Ltd Gorey Road</p><p>Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>&nbsp;</p><p>Saudi Arabia</p><p>Les Laboratoires Servier Scientific Office Al-Sulaimaniah, Al-Safwah building Riyadh, Saudi Arabia.</p><p>Tel: +966 (11) 2886813</p><p>E-mail: fawaz.al-anazi@servier.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 04.2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يستخدم إيفابرادين للحد من خطر دخول المستشفى بسبب تفاقم حالة قصور القلب لدى المرضى الذين يعانون من فشل القلب المستقر، المصحوب بأعراض فشل القلب المزمن مع معامل دفق البطين الأيسر البالغ &le; ۳٥ % والذي يكون ذو إيقاع جيبي مع معدل ضربات القلب عند الإستراحة &ge; ۷۰ نبضة في الدقيقة، وهؤلاء النوع من المرضى ينتاولون الجرعة القصوى التي يمكن تحملها من حاصرات البيتا أو لديهم ما يمنعهم ويحظر عليهم تناول حاصرات البيتا.</p><p>حول قصور القلب المزمن:<br />قصور القلب المزمن هو مرض القلب الذي يحدث عندما لا يتمكن القلب من ضخ ما يكفي من الدم لبقية جسمك. الأعراض الأكثر شيوعا لفشل القلب هي ضيق التنفس والتعب وتورم في الكاحل.</p><p>معلومات خاصة بالذبحة الصدرية الثابتة (التي يطلق عليها اسم &quot;الذبحة&quot;):</p><p>إن الذبحة الصدرية الثابتة عبارة عن داء في القلب، يظهر في حال هبوط كمية الأكسيجين الواردة للقلب. ويظهر هذا الداء بصورة عامة بين سن الأربعين والخمسين سنة. وإن البادرة التي قد تظهر عامة في هذا الوضع تتمثل بالألم والضيق على مستوى الصدر. وتظهر الذبحة الصدرية الثابتة عادة في حال تسرّع ضربات القلب بعد مجهود بدني، أو الانفعال، أو التعرض للبرد، أو بعد وجبة طعام. فقد يسبب هذا التسرع في ضربات القلب ألماً في الصدر لدى الأشخاص المصابين بالذبحة الصدرية.</p><p>كيف يعمل بروكورالان؟<br />يعمل بروكورالان تحديدا على تخفيض سرعة ضربات القلب بمقدار بضع ضربات في الدقيقة، حيث يجعل القلب يتطلب كمية أقل من الأكسيجين، وخاصة في الأوضاع التي قد تحدث خلالها نوبة ذبحة صدرية. بهذا يساهم بروكورالان في تخفيض عدد نوبات الذبحة الصدرية.<br />بالإضافة إلى ذلك، ونظرا لأن ارتفاع سرعة ضربات القلب يؤثر سلبيا على أداء القلب الوظيفي وعلى الإنذار الحيوي لدى المرضى المصابين بالقصور القلبي المزمن، فإن فعل إيفابرادين النوعي المخفض لسرعة ضربات القلب يساعد على تحسين أداء القلب الوظيفي والإنذار الحيوي لدى هؤلاء المرضى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. لا تتناول بروكورالان</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعاني من حساسية تجاه مادة الإيفابرادين أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦)؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كانت ضربات قلبك، في وضعية الاستراحة، بطيئة جداً (أي دون 70 ضربة في الدقيقة)؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال عانيت من إصابة قلبية (أي إصابة قلبية استوجبت إدخالك المستشفى)؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت مصاباً باضطراب في ضربات القلب؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن أصبت مؤخراً بصدمة قلبية؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال كان ضغطك الشریاني منخفض جدا؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من ذبحة صدرية غير مستقرة (نوع شدید یسبب آلاما متكررة على مستوى الصدر مع أو</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بدون مجھود)؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت مصاباً بقصور قلبي وساءت حالتك مؤخرا؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كانت ضربات قلبك تعتمد كليا على الناظمة القلبية التي تحملها (pacemaker)؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت مصاباً بمرض خطير في الكبد؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تأخذ أدویة لمعالجة الإنتانات الفطریة (منھا الكیتوكونازول، والإیتراكونازول)، أو مضادات حیویة من عائلة الماكرولاید (منھا الجوزامایسین، والكلاریترومایسین، والتیلیثرومایسین أو الإریثرومایسین التي تؤخذ عن طریق الفم)، أو الأدویة المستعملة في معالجة الإصابة بالإیدز HIV (منھا النلفینافیر، والریتونافیر)، أو النیفازودون (دواء لمعالجة الاكتئاب)، أو دیلتیازم، فیرابامیل (الذین یستعملان لعلاج ضغط الدم المرتفع أو الذبحة الصدریة</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنتِ امرأة یمكنك الحمل ولا تستعملین وسیلة موثوقة لمنع الحمل؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنتِ حاملا أو تحاولین أن تصبحي حاملا؛</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنتِ مرضع.</p><p>&nbsp;</p><p>ب. اتخذ عناية خاصة لدى استعمال بروكورالان</p><p>تحدث إلى طبيبك، أو مزود الرعاية الصحية أو الصيدلاني قبل تناول بروكورالان</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من اضطرابات في ضربات القلب (مثل ضربات القلب غير المنتظمة، خفقان، زيادة الألم على مستوى الصدر) أو رجفان أذيني مستمر (نوع من ضربات القلب غير المنتظمة)، أو من مظهر غير طبيعي في مخطط القلب الكهربائي (ECG) يطلق عليه اسم &quot;متلازمة تطاول QT&quot;،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كانت تظهر لديك بوادر إرهاق أو دوار أو ضيق في التنفس (هذا قد يعني أن ضربات قلبك بطيئة جداً)،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعاني من أعراض الرجفان الأذیني (معدل النبض أثناء الراحة مرتفع بشكل غیر طبیعي (أكثر</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من ۱۱۰ ضربة بالدقیقة) أو غیر منتظم، دون أي سبب ظاھر، مما یجعل عدّھا صعبا)،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت قد أصبت مؤخّراً بسكتة دماغية (أي نوبة مخيّة)،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كان لديك انخفاض في الضغط الشرياني بدرجة خفيفة إلى متوسطة،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تعاني من ضغط شرياني غير خاضع للسيطرة، وخاصة بعد تغيير العلاج المضاد لارتفاع الضغط،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من القصور القلبي المزمن أو من قصور القلب المترافق بمظهر غير طبيعي في مخطط القلب الكهربائي (ECG) يطلق عليه اسم&nbsp; &quot;إحصار فرع الحزيمة&quot;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من مرض مزمن في شبكة العين،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من اضطرابات كبدية متوسطة،</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن كنت تشكو من اضطرابات كلوية شديدة.</p><p>فإن كان وضعك مطابقا لإحدى الحالات المذكورة أعلاه، فاستشر طبيبك أو مزود الرعاية الصحية بسرعة قبل أو وقت مداواتك بواسطة بروكورالان.</p><p><u>&nbsp;</u></p><p>الأطفال</p><p>لا يجوز استعمال بروكورالان لدى الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ سنة.</p><p>&nbsp;</p><p>ج. تناول الأدوية الأخرى، المكملات العشبية أو الغذائية</p><p>عليك بأن تُعلم طبيبك، أو مزوّد الرعاية الصحية أو الصيدلاني إن كنت تتناول حاليا أو تناولت مؤخّراً أو قد تتناول أي دواء آخر.</p><p>&nbsp;</p><p>احرص على إعلام طبيبك، أو مزوّد الرعاية الصحية أو الصيدلاني إن كنت تأخذ أياً من الأدوية التالية التي تستلزم تسوية جرعة بروكورالان أو تستوجب مراقبة خاصة:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فلوكونازول (دواء مضاد للفطار)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ريفامبيسين (مضاد حيوي)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بربيتورات (لمعالجة الأرق والصرع)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فينيتويين (لمعالجة الصرع)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هيبيريكوم برفوراتوم أو St John&rsquo;s Wort (علاج عشبي للاكتئاب)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية التي من شأنها أن تسبب تطاول فترة QT والمستعملة سواء في علاج اضطرابات النظم القلبي أو أمراض أخرى:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كينيدين، ديزوبيراميد، إيبوتيليد، سوتالول، أميودارون (لمعالجة اضطرابات ضربات القلب</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بيبريديل (لمعالجة الذبحة الصدرية)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بعض أنواع الأدوية المستعملة في معالجة القلق، أو الفصام، أو غيرها من الإصابات الذهانية (منها بيموزيد، وزيبرازيدون، وسرتندول)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية المضادة للملاريا) (منها: ميفلوكين، أو هالوفانترين)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إيريترومايسين عن طريق الوريد (مضاد حيوي)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بنتاميدين (مضاد طفيلي)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيزابرايد (لمعالجة الجزر المعِدي)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بعض الأدوية المدّرة للبول التي قد تسبب انخفاض معدّل البوتاسيوم في الدم، مثل فيوروسيمايد، هيدروكلوروثيازيد، إنداباميد (التي تستعمل لعلاج الوذمة وارتفاع ضغط الدم).</p><p>&nbsp;</p><p>د. تناول بروكورالان مع الطعام والشراب</p><p>تجنّب تناول عصير الليمون الهندي (grapefruit) وقت العلاج بواسطة بروكورالان.</p><p>&nbsp;</p><p>هـ. الحمل والإرضاع</p><p>لا یجوز أن تتناولي بروكورالان إن كنت حامل، أو إن كنت تخططین للحمل والإنجاب (أنظري إلى مقطع &quot;لا</p><p>تتناول بروكورالان&quot;).</p><p>فإن كنت حاملا وقت علاجك بواسطة بروكورالان, تحدثي إلى طبیبك أو مزوّد الرعایة الصحیة بھذا الشأن.</p><p>لا یجوز أن تتناولي بروكورالان إن كان بإمكانك أن تصبحي حاملا إلا إذا كنتِ تستعملین وسائل موثوقة لمنع</p><p>الحمل (أنظري إلى مقطع &quot;لا تتناول بروكورالان&quot;).</p><p>لا یجوز أن تتناولي بروكورالان إذا كنت مرضعا (أنظري إلى مقطع &quot;لا تتناول بروكورالان). تحدثي إلى طبیبك</p><p>أو مزوّد الرعایة الصحیة إذا كنت مرضعا أو تنوین أن ترضعي لأنھ یجب التوقف عن الإرضاع في حال تناول</p><p>بروكورالان.</p><p>إذا كنت حاملا أو مرضعا،ً أو تعتقدین بأنك قد تكونین حاملا،ً أو تخططین للحمل والإنجاب، فاطلبي نصیحة</p><p>الطبیب، أو مزوّد الرعایة الصحیة أو الصیدلاني قبل تناول ھذا الدواء.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>و. قيادة السيارات واستعمال الآليات</p><p>قد يسبب بروكورالان ومضات برّاقة عابرة في النظر (ومضة قصيرة تظهر في مجال الرؤية، أنظر إلى مقطع &quot;الآثار الجانبية المتوقعة&quot;). فإن حصل لك هذا، عليك بالحذر إن كنت تقود سيارة أو إن كنت تعمل على الآليات، فقد تُفاجأ بتبدّل في شدة الضوء، وخاصة إن كنت تقود السيارة أثناء الليل.</p><p>&nbsp;</p><p>ز. معلومات هامة تتعلق ببعض مكونات بروكورالان</p><p>يحتوي بروكورالان على اللاكتوز (سكر الحليب).</p><p>&nbsp;</p><p>إذا كان طبيبك قد سبق وأعلمك بأنك مصاب بعدم تحمّل لبعض أنواع السكاكر، عليك باستشارة الطبيب أو مزوّد الرعاية الصحية قبل المباشرة بتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عند استعمال ھذا الدواء تقیّد دائما بوصفة الطبیب أو مزوّد الرعایة الصحیة أو الصیدلاني. وفي حال الشك استشر</p><p>الطبیب أو مزوّد الرعایة الصحیة أو الصیدلاني.</p><p>یجب أن یؤخذ بروكورالان أثناء وجبة الطعام.</p><p>إذا كنت تتعالج من الذبحة الصدریة المستقرة</p><p>یجب ألا تتجاوز الجرعة الابتدائیة حبّة واحدة من بروكورالان ٥ ملغ تؤخذ مرتین في الیوم. إذا كنت لاتزال تعاني</p><p>من أعراض الذبحة الصدریة، وإذا تحملت جرعة ال ٥ ملغ مرتین یومیا، فیمكن رفع الجرعة. یجب ألا تتجاوز</p><p>جرعة المداومة مقدار ۷٫٥ ملغ مرتین یومیا. سیصف لك طبیبك أو مزود الرعایة الصحیة الجرعة المناسبة لك.</p><p>الجرعة المعتادة عبارة عن حبة في الصباح وحبة عند المساء. في بعض الحالات (وخاصة لدى المتقدمین في</p><p>السن)، قد یصف لك طبیبك أو مزوّد الرعایة الصحیة نصف ھذه الجرعة، أي نصف حبة بروكورالان ٥ ملغ (بما</p><p>یعادل ملغ من ۲٫٥ الإیفابرادین) في الصباح ونصف حبة بروكورالان ٥ ملغ عند المساء.</p><p>&nbsp;</p><p>أ. إذا تناولت جرعة أكبر مما یجب من بروكورالان:</p><p>إن أخذ جرعة فائقة من بروكورالان قد یسبب حالة صعوبة التنفس أو التعب، بسبب انخفاض معدّل ضربات قلبك</p><p>بشكل كبیر. فإن حدث لك ھذا اتصل فورا بطبیبك أو مزوّد الرعایة الصحیة.</p><p>&nbsp;</p><p>ب. إذا نسیت تناول جرعة بروكورالان:</p><p>إن سھوت عن أخذ جرعة بروكورالان، خذ الجرعة التالیة في وقتھا الاعتیادي. ولا یجوز على الإطلاق مضاعفة</p><p>مقدار الجرعة تعویضا عن الجرعة التي سھوت عن تناولھا.</p><p>إن التقویم المطبوع على الصفیحة الحاویة للحبّات یذكرك بآخر موعد أخذت فیھ حبّة بروكورالان.</p><p>&nbsp;</p><p>ج. في حال التوقف عن تناول بروكورولان:</p><p>إن علاج الذبحة الصدریة أو قصور القلب المزمن علاج مدى الحیاة . فلا یجو ز التوقف ع ن ھذ ا العلاج قبل</p><p>استشارة الطبیب أو مزوّد الرعایة الصحیة.</p><p>فإن بدا لك بأن بروكورالان شدید أو قلیل الفعالیة بالنسبة إلیك، راجع الطبیب أو مزوّد الرعایة الصحیة أو</p><p>الصیدلاني.</p><p>&nbsp;</p><p>فإن كانت لدیك أي أسئلة تتعلق باستعمال ھذا الدواء، فاسأل طبیبك أو مزوّد الرعایة الصحیة أو الصیدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما ھو الحال مع كافة الأدویة، فقد یسبب ھذا الدواء آثارا جانبیةً، رغم أنھا لا تصیب كافة الأشخاص.</p><p>یتم تحدید معدل حدوث الآثار الجانبیة المحتملة المبینة أدناه باستعمال القاعدة التالیة:شائعة جدا:ً قد تحدث لدى أكثر</p><p>من ۱ من كل ۱۰ أشخاص</p><p>شائعة: قد تحدث لدى ما لا یزید عن ۱ من كل ۱۰ أشخاص</p><p>غیر شائعة: قد تحدث لدى ما لا یزید عن ۱ من كل ۱۰۰ شخص</p><p>نادرة: قد تحدث لدى ما لا یزید عن ۱ من كل ۱۰۰۰ شخص</p><p>نادرة جدا:ً قد تحدث لدى ما لا یزید عن ۱ من كل ۱۰۰۰۰ شخص</p><p>غیر معروفة المعدّل، لا یمكن تقدیر معدل الحدوث بناءً على البیانات المتوفرة</p><p>&nbsp;</p><p>التأثیرات العكسیة الأكثر شیوعا لدى استعمال ھذا الدواء تعتمد على الجرعة المتناولة وترتبط بطریقة تأثیر الدواء:</p><p>شائعة جدا:</p><p>ومیض في العینین (الإحساس بالنور الفائق لفترات قصیرة، یحصل غالبا وقت التغییر الفجائي لحدة النور). ویمكن</p><p>وصفھا بأنھا ھالات ضوئیة، أو ومضات ملونة، أو تفكّك الصور أو تعدّد الصور. وھي تحدث بشكل عام خلال</p><p>الشھرین الأولین من العلاج وبعد ذلك قد یتكرر حدوثھا وتتراجع أثناء العلاج أو بعده.</p><p>شائعة:</p><p>تأثیرات على عمل القلب (تتمثل الأعراض في تباطؤ سرعة القلب). وھي تحدث بشكل خاص خلال الشھرین &ndash;</p><p>الثلاثة شھور الأولى من بدء العلاج.</p><p>وقد تم الإبلاغ عن آثار جانبیة أخرى:</p><p>شائعة:</p><p>تقلصات سریعة غیر منتظمة في القلب، شعور غیر عادي بضربات القلب، ضغط دم غیر خاضع للسیطرة،</p><p>صداع، دوار، عدم وضوح الرؤیة (رؤیة ضبابیة).</p><p>غیر شائعة:</p><p>خفقان القلب وضربات زائدة للقلب، شعور بالإعیاء (غثیان)، إمساك<strong>، ألم في البطن</strong>، إسھال، دوار، ضیق التنفس،</p><p>تشنجات عضلیة، تغیرات في المقاییس الحیویة: مستویات عالیة من حمض الیوریك في الدم، فرط الیوزینیات</p><p>(نوع من خلایا الدم البیضاء)، ارتفاع مستوى الكریاتینین في الدم (إفرازات عضلیة منحلة)، طفح جلدي، وذمة</p><p>وعائیّة (مثل التضخّم في الوجھ أو في اللسان أو في البلعوم، صعوبة في التنفس أو في البلع)، انخفاض الضغط</p><p>،(ECG) الشریاني، إغماء، الشعور بالتعب، الشعور بالضعف، نتائج غیر طبیعیة لمخطط القلب الكھربائي</p><p>ازدواج الرؤیة، اضطراب الرؤیة.</p><p>نادرة:</p><p>شرى، حكّة، احمرار جلدي، الإحساس بالوعكة.</p><p>نادرة جدا:</p><p>ضربات قلب غیر منتظمة.</p><p>&nbsp;</p><p>إذا أصبت بأي آثار جانبیة، فالرجاء إبلاغ طبیبك، أو مزوّد الرعایة الصحیة، أو الصیدلاني. وھذا یشمل ظھور أي</p><p>آثار جانبیة محتملة لم یرد ذكرھا في ھذه النشرة. یمكنك أیضا الإبلاغ عن التأثیرات الجانبیة مباشرة عن طریق</p><p>نظام الإبلاغ الوطني. عند إبلاغك عن الآثار الجانبیة فأنت تساعد بتقدیم مزید من المعلومات عن سلامة ھذا</p><p>الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا عن مرأى الأطفال وعن متناول أيديهم.</p><p>احفظه &nbsp;في مكان لا تزيد درجة حرارته عن ٣٠ درجة مئوية، وفي عبوته الأصلية.</p><p>لا تستعمل هذا الدواء بعد انقضاء تاريخ الفعالية المبيّن على العلبة وعلى الصفيحة المضغوطة بعد الرمز &lsquo;EXP&rsquo;. يستند تاريخ انتهاء الفعالية إلى آخر يوم من الشهر المشار إليه.</p><p>&nbsp;</p><p>لا تتخلص من إي مواد دوائية في مياه المجاري العامة أو مع قمامة المنزل.&nbsp; اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي إيفابرادين (على شكل هيدروكلورايد).</p><p>&nbsp;&nbsp; بروكورالان ٥ ملغ: كل حبة ملبسة تحتوي على ٥ ملغ من الإيفابرادين (بما يساوي ٥٫٣٩٠ ملغ&nbsp;&nbsp;</p><p>&nbsp; &nbsp;إيفابرادين على شكل هيدروكلورايد).</p><p>&nbsp;&nbsp; بروكورالان ٥,٧ ملغ: كل حبة ملبسة تحتوي على ٥,٧ ملغ من الإيفابرادين (بما يساوي&nbsp;٠٨٥,٨ ملغ</p><p>&nbsp; &nbsp;إيفابرادين على شكل هيدروكلورايد).</p><p>-&nbsp; المكونات الأخرى الموجودة داخل القرص هي: سكر الحليب أحادي الماء، ستيريات المغنيزيوم</p><p>&nbsp;&nbsp; (E 470B)، نشاء الذرة، مالتودكسترين، السيليكا الغروانية اللامائية (E 551). والمكونات &nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp; الموجودة في غلاف القرص: هيبروملوز (E 464)، ثاني أكسيد التيتانيوم (E 171)،</p><p>&nbsp;&nbsp; ماكروغول 6000، غليسيرول (E 422)، ستيريات المغنيزيوم (E 470B)، أكسيد الحديد</p><p>&nbsp;&nbsp; الأصفر (E 172)، أكسيد الحديد الأحمر (E 172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            إن حبّات بروكورالان ٥ ملغ هي من لون برتقالي، متطاولة الشكل، ملبسة، تحتوي على خط قاطع للقسم، وجهيها، نُقش على وجه منها عدد " 5 " وعلى الوجه الآخر شكل  .
وإن حبّات بروكورالان ٥,٧ ملغ هي من لون برتقالي، مثلّثة الشكل، ملبسة، نقش على وجه منها عدد " 7.5" وعلى الوجه الآخر شكل  .

تتوفر الحبات في أغلفة مرتبة حسب جدول زمني (أغلفة بلاستيكية مصنوعة من ألمنيوم/PVC) تحتوي على ١٤ أو ٢٨ أو ٥٦ أو ٨٤ أو ٩٨ أو ١٠٠ أو ١١٢حبة. 
قد لا يتم تسويق كافة حجوم العبوات.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><u>صاحب إجازة التسويق:</u></p><p>مختبرات سيرفييه</p><p>Les Laboratoires Servier</p><p>50 rue Carnot</p><p>92284 Suresnes cedex</p><p>France</p><p>&nbsp;</p><p><u>التصنيع:</u></p><p>سيـرفييـه (إيرلندا) للتصنيع المحدودة</p><p>Servier (Ireland) Industries Ltd</p><p>Gorey Road</p><p>Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p>&nbsp;</p><p>للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة لإجازة التسويق.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:217.95pt"><p>المملكة العربية السعودية</p><p>المكتب العلمي لمختبرات سيرفييه</p><p>السليمانية، بناء الصفوة</p><p>الرياض، المملكة العربية السعودية</p><p>هاتف: ٩٦٦١٢٨٨٦٨١٣+</p><p>البريد الالكتروني&uml;</p><p>fawaz.al-anazi@sa.netgrs.com</p></td><td style="vertical-align:top; width:218.0pt"><p>بلدان الخليج</p><p>المكتب العلمي لمختبرات سيرفييه</p><p>ص.ب. ١٥٨٦، أبراج API، رقم المكتب ٨٠١</p><p>طريق الشيخ زايد، دبي، الإمارات العربية المتحدة</p><p>هاتف: ٩٧١٤٣٣٢٩٩٠٣+</p><p>البريد الالكتروني:&nbsp;&nbsp; magdy.abdou@ae.netgrs.com</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة في 04-2017.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Procoralan 5 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine as
hydrochloride).
Excipient with known effect: 63.91 mg lactose monohydrate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Salmon-coloured, oblong, film-coated tablet scored on both sides, engraved with “5” on one face
and on the other face.
The tablet can be divided into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction  35%, who are in sinus rhythm with resting heart rate  70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />For the different doses, film-coated tablets containing 5 mg and 7.5 mg ivabradine are available. The treatment has to be initiated only in patient with stable heart failure. It is recommended that the treating physician should be experienced in the management of chronic heart failure. The usual recommended starting dose of ivabradine is 5 mg twice daily. After two weeks of treatment, the dose can be increased to 7.5 mg twice daily if resting heart rate is persistently above 60 bpm or decreased to 2.5 mg twice daily (one half 5 mg tablet twice daily) if resting heart rate is persistently below 50 bpm or in case of symptoms related to bradycardia such as dizziness, fatigue or hypotension. If heart rate is between 50 and 60 bpm, the dose of 5 mg twice daily should be maintained. If during treatment, heart rate decreases persistently below 50 beats per minute (bpm) at rest or the patient experiences symptoms related to bradycardia, the dose must be titrated downward to the next lower dose in patients receiving 7.5 mg twice daily or 5 mg twice daily. If heart rate increases persistently above 60 beats per minute at rest, the dose can be up titrated to the next upper dose in patients receiving 2.5 mg twice daily or 5 mg twice daily.<br />Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist (see section 4.4).</p><p>Special population<br />Older people<br />In patients aged 75 years or more, a lower starting dose should be considered (2.5 mg twice daily i.e. one half 5 mg tablet twice daily) before up-titration if necessary.<br />Patients with renal impairment<br />No dose adjustment is required in patients with renal insufficiency and creatinine clearance above 15 ml/min (see section 5.2).<br />No data are available in patients with creatinine clearance below 15 ml/min. Ivabradine should therefore be used with precaution in this population.<br />Patients with hepatic impairment<br />No dose adjustment is required in patients with mild hepatic impairment. Caution should be exercised when using ivabradine in patients with moderate hepatic impairment. Ivabradine is contra-indicated for use in patients with severe hepatic insufficiency, since it has not been studied in this population and a large increase in systemic exposure is anticipated (see sections 4.3 and 5.2).<br />Paediatric population<br />The safety and efficacy of ivabradine in children aged below 18 years have not yet been established.<br />No data are available.<br />Method of administration<br />Tablets must be taken orally twice daily, i.e. once in the morning and once in the evening during meals (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

- Resting heart rate below 70 beats per minute prior to treatment

- Cardiogenic shock

- Acute myocardial infarction

- Severe hypotension (< 90/50 mmHg)

- Severe hepatic insufficiency

- Sick sinus syndrome

- Sino-atrial block

- Unstable or acute heart failure

- Pacemaker dependent (heart rate imposed exclusively by the pacemaker)

- Unstable angina

- AV-block of 3rd degree

- Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals

(ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2)

- Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5)

- Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Special warnings</u><br />Measurement of heart rate<br />Given that the heart rate may fluctuate considerably over time, serial heart rate measurements, ECG or ambulatory 24-hour monitoring should be considered when determining resting heart rate before initiation of ivabradine treatment and in patients on treatment with ivabradine when titration is considered. This also applies to patients with a low heart rate, in particular when heart rate decreases<br />below 50 bpm, or after dose reduction (see section 4.2).<br />Cardiac arrhythmias<br />Ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely loses its efficacy when a tachyarrhythmia occurs (eg. ventricular or supraventricular tachycardia). Ivabradine is therefore not recommended in patients with atrial fibrillation or other cardiac arrhythmias that interfere with sinus node function.<br />In patients treated with ivabradine the risk of developing atrial fibrillation is increased (see section 4.8). Atrial fibrillation has been more common in patients using concomitantly amiodarone or potent class I anti-arrhythmics. It is recommended to regularly clinically monitor ivabradine treated patients for the occurrence of atrial fibrillation (sustained or paroxysmal), which should also include ECG<br />monitoring if clinically indicated (e.g. in case of exacerbated angina, palpitations, irregular pulse). Patients should be informed of signs and symptoms of atrial fibrillation and be advised to contact their physician if these occur.<br />If atrial fibrillation develops during treatment, the balance of benefits and risks of Ccntinued ivabradine treatment should be carefully reconsidered.<br />Chronic heart failure patients with intraventricular conduction defects (bundle branch block left, bundle branch block right) and ventricular dyssynchrony should be monitored closely.<br />Use in patients with AV-block of 2nd degree<br />Ivabradine is not recommended in patients with AV-block of 2nd degree.<br />Use in patients with a low heart rate<br />Ivabradine must not be initiated in patients with a pre-treatment resting heart rate below 70 beats per minute (see section 4.3).<br />If, during treatment, resting heart rate decreases persistently below 50 bpm or the patient experiences symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose must be titrated downward or treatment discontinued if heart rate below 50 bpm or symptoms of bradycardia persist (see section 4.2).</p><p>Combination with calcium channel blockers<br />Concomitant use of ivabradine with heart rate reducing calcium channel blockers such as verapamil or diltiazem is contraindicated (see sections 4.3 and 4.5). No safety issue has been raised on the combination of ivabradine with nitrates and dihydropyridine calcium channel blockers such as amlodipine. Additional efficacy of ivabradine in combination with dihydropyridine calcium channel blockers has not been established (see section 5.1).<br />Chronic heart failure<br />Heart failure must be stable before considering ivabradine treatment. Ivabradine should be used with caution in heart failure patients with NYHA functional classification IV due to limited amount of data in this population.<br />Stroke<br />The use of ivabradine is not recommended immediately after a stroke since no data is available in these situations.</p><p>Visual function<br />Ivabradine influences on retinal function (see section 5.1). To date, there is no evidence of a toxic effect of ivabradine on the retina, but the effects of long-term ivabradine treatment beyond one year on retinal function are currently not known. Cessation of treatment should be considered if any unexpected deterioration in visual function occurs. Caution should be exercised in patients with retinitis pigmentosa.</p><p><u>Precautions for use</u><br />Patients with hypotension<br />Limited data are available in patients with mild to moderate hypotension, and ivabradine should therefore be used with caution in these patients. Ivabradine is contra-indicated in patients with severe hypotension (blood pressure &lt; 90/50 mmHg) (see section 4.3).<br />Atrial fibrillation - Cardiac arrhythmias<br />There is no evidence of risk of (excessive) bradycardia on return to sinus rhythm when<br />pharmacological cardioversion is initiated in patients treated with ivabradine. However, in the absence of extensive data, non urgent DC-cardioversion should be considered 24 hours after the last dose of ivabradine.<br />Use in patients with congenital QT syndrome or treated with QT prolonging medicinal products The use of ivabradine in patients with congenital QT syndrome or treated with QT prolonging medicinal products should be avoided (see section 4.5). If the combination appears necessary, close cardiac monitoring is needed.<br />Heart rate reduction, as caused by ivabradine, may exacerbate QT prolongation, which may give rise to severe arrhythmias, in particular Torsade de pointes.<br />Hypertensive patients requiring blood pressure treatment modifications.<br />In the SHIFT trial more patients experienced episodes of increased blood pressure while treated with ivabradine (7.1%) compared to patients treated with placebo (6.1%). These episodes occurred most frequently shortly after blood pressure treatment was modified, were transient, and did not affect the treatment effect of ivabradine. When treatment modifications are made in chronic heart failure patients treated with ivabradine blood pressure should be monitored at an appropriate interval (see section 4.8).<br />Excipients<br />Since tablets contain lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u><br />Concomitant use not recommended<br />QT prolonging medicinal products<br />- Cardiovascular QT prolonging medicinal products (e.g. quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone).<br />- Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin).<br />The concomitant use of cardiovascular and non cardiovascular QT prolonging medicinal products with ivabradine should be avoided since QT prolongation may be exacerbated by heart rate reduction. If the combination appears necessary, close cardiac monitoring is needed (see section 4.4).<br />Concomitant use with precaution<br />Potassium-depleting diuretics (thiazide diuretics and loop diuretics): hypokalemia can increase the risk of arrhythmia. As ivabradine may cause bradycardia, the resulting combination of hypokalemia and &nbsp;bradycardia is a predisposing factor to the onset of severe arrhythmias, especially in patients with long QT syndrome, whether congenital or substance-induced.</p><p><u>Pharmacokinetic interactions</u><br />Cytochrome P450 3A4 (CYP3A4)<br />Ivabradine is metabolised by CYP3A4 only and it is a very weak inhibitor of this cytochrome. Ivabradine was shown not to influence the metabolism and plasma concentrations of other CYP3A4 substrates (mild, moderate and strong inhibitors). CYP3A4 inhibitors and inducers are liable to interact with ivabradine and influence its metabolism and pharmacokinetics to a clinically significant extent. Drug-drug interaction studies have established that CYP3A4 inhibitors increase ivabradine plasma concentrations, while inducers decrease them. Increased plasma concentrations of&nbsp; ivabradine may be associated with the risk of excessive bradycardia (see section 4.4).<br />Contra-indication of concomitant use<br />The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole,<br />itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contra-indicated (see section 4.3). The potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily) increased ivabradine mean plasma exposure by 7 to 8 fold.<br />Moderate CYP3A4 inhibitors: specific interaction studies in healthy volunteers and patients have shown that the combination of ivabradine with the heart rate reducing agents diltiazem or verapamil resulted in an increase in ivabradine exposure (2 to 3 fold increase in AUC) and an additional heart rate reduction of 5 bpm. The concomitant use of ivabradine with these medicinal products is contraindicated (see section 4.3).<br />Concomitant use not recommended<br />Grapefruit juice: ivabradine exposure was increased by 2-fold following the co-administration with grapefruit juice. Therefore the intake of grapefruit juice should be avoided.<br />Concomitant use with precautions<br />- Moderate CYP3A4 inhibitors: the concomitant use of ivabradine with other moderate CYP3A4 inhibitors (e.g. fluconazole) may be considered at the starting dose of 2.5 mg twice daily and if resting heart rate is above 70 bpm, with monitoring of heart rate.<br />- CYP3A4 inducers: CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin, Hypericum<br />perforatum [St John&rsquo;s Wort]) may decrease ivabradine exposure and activity. The concomitant use of CYP3A4 inducing medicinal products may require an adjustment of the dose of ivabradine. The combination of ivabradine 10 mg twice daily with St John&rsquo;s Wort was shown to reduce ivabradine AUC by half. The intake of St John&rsquo;s Wort should be restricted during the treatment with ivabradine.</p><p>Other concomitant use<br />Specific drug-drug interaction studies have shown no clinically significant effect of the following medicinal products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors (omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine, lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the pharmacodynamics of aspirin.</p><p>In pivotal phase III clinical trials the following medicinal products were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other antiplatelet medicinal products.</p><p>Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential<br />Women of child-bearing potential should use appropriate contraceptive measures during treatment (see section 4.3).<br />Pregnancy<br />There are no or limited amount of data from the use of ivabradine in pregnant women.<br />Studies in animals have shown reproductive toxicity. These studies have shown embryotoxic and teratogenic effects (see section 5.3). The potential risk for humans is unknown. Therefore, ivabradine is contra-indicated during pregnancy (see section 4.3).<br />Breast-feeding<br />Animal studies indicate that ivabradine is excreted in milk. Therefore, ivabradine is contra-indicated during breast-feeding (see section 4.3).<br />Women that need treatment with ivabradine should stop breast-feeding, and choose for another way of feeding their child.<br />Fertility<br />Studies in rats have shown no effect on fertility in males and females (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific study to assess the possible influence of ivabradine on driving performance has been performed in healthy volunteers where no alteration of the driving performance was evidenced. However, in post-marketing experience, cases of impaired driving ability due to visual symptoms have been reported. Ivabradine may cause transient luminous phenomena consisting mainly of phosphenes (see section 4.8). The possible occurrence of such luminous phenomena should be taken into account when driving or using machines in situations where sudden variations in light intensity may occur,<br />especially when driving at night.</p><p>Ivabradine has no influence on the ability to use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Ivabradine has been studied in clinical trials involving nearly 45,000 participants.<br />The most common adverse reactions with ivabradine, luminous phenomena (phosphenes) and bradycardia, are dose dependent and related to the pharmacological effect of the medicinal product.<br />Tabulated list of adverse reactions<br />The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (&sup3;1/10); common (&sup3;1/100 to &lt;1/10); uncommon (&sup3;1/1,000 to &lt;1/100); rare (&sup3;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>System Organ Class</td><td>Frequency</td><td>Prefered Term</td></tr><tr><td>Blood and lymphatic system<br />disorders</td><td>Uncommon</td><td>Eosinophilia</td></tr><tr><td>Metabolism and nutrition<br />disorders</td><td>Uncommon</td><td>Hyperuricaemia</td></tr><tr><td>Nervous system disorders</td><td>Common</td><td>Headache, generally during the first month<br />of treatment</td></tr><tr><td>Nervous system disorders</td><td>Common</td><td>Dizziness, possibly related to bradycardia</td></tr><tr><td>Nervous system disorders</td><td>Uncommon*</td><td>Syncope, possibly related to bradycardia</td></tr><tr><td>Eye disorders</td><td>Very common</td><td>Luminous phenomena (phosphenes)</td></tr><tr><td>Eye disorders</td><td>Common</td><td>Blurred vision</td></tr><tr><td>Eye disorders</td><td>Uncommon*</td><td>Diplopia</td></tr><tr><td>Eye disorders</td><td>Uncommon*</td><td>Visual impairment</td></tr><tr><td>Ear and labyrinth disorders</td><td>Uncommon</td><td>Vertigo</td></tr><tr><td>Cardiac disorders</td><td>Common</td><td>Bradycardia</td></tr><tr><td>Cardiac disorders</td><td>Common</td><td>AV 1st degree block (ECG prolonged PQ<br />interval)</td></tr><tr><td>Cardiac disorders</td><td>Common</td><td>Ventricular extrasystoles</td></tr><tr><td>Cardiac disorders</td><td>Common</td><td>Atrial fibrillation</td></tr><tr><td>Cardiac disorders</td><td>Uncommon</td><td>Palpitations, supraventricular extrasystoles</td></tr><tr><td>Cardiac disorders</td><td>Very rare</td><td>AV 2nd degree block, AV 3rd degree block</td></tr><tr><td>Cardiac disorders</td><td>Very rare</td><td>Sick sinus syndrome</td></tr><tr><td>Vascular disorders</td><td>Common</td><td>Uncontrolled blood pressure</td></tr><tr><td>Vascular disorders</td><td>Uncommon*</td><td>Hypotension, possibly related to<br />bradycardia</td></tr><tr><td>Respiratory, thoracic and<br />mediastinal disorders</td><td>Uncommon</td><td>Dyspnoea</td></tr><tr><td>Gastrointestinal disorders</td><td>Uncommon</td><td>Nausea</td></tr><tr><td>Gastrointestinal disorders</td><td>Uncommon</td><td>Constipation</td></tr><tr><td>Gastrointestinal disorders</td><td>Uncommon</td><td>Diarrhoea</td></tr><tr><td>Gastrointestinal disorders</td><td>Uncommon</td><td>Abdominal pain*</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td>Uncommon*</td><td>Angioedema</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td>Uncommon*</td><td>Rash</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td>Rare*</td><td>Erythema</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td>Rare*</td><td>Pruritus</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td>Rare*</td><td>Urticaria</td></tr><tr><td>Musculoskeletal and connective<br />tissue disorders</td><td>Uncommon</td><td>Muscle cramps</td></tr><tr><td>General disorders and<br />administration site conditions</td><td>Uncommon</td><td>Asthenia, possibly related to bradycardia</td></tr><tr><td>General disorders and<br />administration site conditions</td><td>Uncommon*</td><td>Fatigue, possibly related to bradycardia</td></tr><tr><td>General disorders and<br />administration site conditions</td><td>Rare*</td><td>Malaise, possibly related to bradycardia</td></tr><tr><td>Investigations</td><td>Uncommon</td><td>Elevated creatinine in blood</td></tr><tr><td>Investigations</td><td>Uncommon</td><td>ECG prolonged QT interval</td></tr></tbody></table><p>* Frequency calculated from clinical trials for adverse events detected from spontaneous report</p><p>Description of selected adverse reactions<br />Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightness in a limited area of the visual field. They are usually triggered by sudden variations in light intensity. Phosphenes may also be described as a halo, image decomposition (stroboscopic or kaleidoscopic effects), coloured bright lights, or multiple image (retinal persistency). The onset of phosphenes is generally within the first two months of treatment after which they may&nbsp;occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity. All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment. Fewer than 1% of patients changed their daily routine or discontinued the treatment in relation with phosphenes.</p><p>Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiation. 0.5% of patients experienced a severe bradycardia below or equal to 40 bpm.</p><p>In the SIGNIFY study atrial fibrillation was observed in 5.3% of patients taking ivabradine compared to 3.8% in the placebo group. In a pooled analysis of all the Phase II/III double blind controlled clinical trials with a duration of at least 3 months including more than 40,000 patients, the incidence of atrial fibrillation was 4.86% in ivabradine treated patients compared to 4.08% in controls, corresponding to a hazard ratio of 1.26, 95% CI [1.15-1.39].</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p><br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- National Pharmacovigilance Center (NPC)<br />- Fax: +966-11-205-7662<br />- Call NPC at +966-11-2038222, Exts:2317-2356-2353-2354-2334-2340.<br />- Toll free phone: 8002490000<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u><br />Overdose may lead to severe and prolonged bradycardia (see section 4.8).<br /><u>Management</u><br />Severe bradycardia should be treated symptomatically in a specialised environment. In the event of bradycardia with poor haemodynamic tolerance, symptomatic treatment including intravenous betastimulating medicinal products such as isoprenaline may be considered. Temporary cardiac electrical pacing may be instituted if required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations, ATC code: C01EB17.<br /><u>Mechanism of action</u><br />Ivabradine is a pure heart rate lowering agent, acting by selective and specific inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.</p><p>Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If. It participates in the temporal resolution of the visual system, by curtailing the retinal response to bright light stimuli. Under triggering circumstances (e.g. rapid changes in luminosity), partial inhibition of Ih by ivabradine underlies the luminous phenomena that may be occasionally experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field (see section 4.8).</p><p><u>Pharmacodynamic effects</u><br />The main pharmacodynamic property of ivabradine in humans is a specific dose dependent reduction in heart rate. Analysis of heart rate reduction with doses up to 20 mg twice daily indicates a trend towards a plateau effect which is consistent with a reduced risk of severe bradycardia below 40 bpm (see section 4.8).<br />At usual recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. This leads to a reduction in cardiac workload and myocardial oxygen consumption. Ivabradine does not influence intracardiac conduction, contractility (no negative inotropic effect) or<br />ventricular repolarisation:<br />- in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or<br />intraventricular conduction times or corrected QT intervals;<br />- in patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30 and 45%), ivabradine did not have any deleterious influence on LVEF.<br /><u>Clinical efficacy and safety</u><br />The efficacy and safety of ivabradine in Chronic Heart Failure was demonstrated in the SHIFT Study. The SHIFT study was a large multicentre, international, randomised double-blind placebo controlled outcome trial conducted in 6505 adult patients with stable chronic CHF (for &sup3; 4 weeks), NYHA class II to IV, with a reduced left ventricular ejection fraction (LVEF &pound; 35%) and a resting heart rate &sup3; 70 bpm.<br />Patients received standard care including beta-blockers (89 %), ACE inhibitors and/or angiotensin II antagonists (91 %), diuretics (83 %), and anti-aldosterone agents (60 %). In the ivabradine group, 67% of patients were treated with 7.5 mg twice a day. The median follow-up duration was 22.9 months. Treatment with ivabradine was associated with an average reduction in heart rate of 15 bpm from a baseline value of 80 bpm. The difference in heart rate between ivabradine and placebo arms was 10.8 bpm at 28 days, 9.1 bpm at 12 months and 8.3 bpm at 24 months.</p><p>The study demonstrated a clinically and statistically significant relative risk reduction of 18% in the rate of the primary composite endpoint of cardiovascular mortality and hospitalisation for worsening heart failure (hazard ratio: 0.82, 95%CI [0.75;0.90] &ndash; p&lt;0.0001) apparent within 3 months of initiation of treatment. The absolute risk reduction was 4.2%. The results on the primary endpoint are mainly driven by the heart failure endpoints, hospitalisation for worsening heart failure (absolute riskreduced by 4.7 %) and deaths from heart failure (absolute risk reduced by 1.1 %).</p><p>Treatment effect on the primary composite endpoint, its components and secondary endpoints</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Ivabradine (N=3241)</p><p>n(%)</p></td><td><p>Placebo (N=3264)</p><p>n(%)</p></td><td>Hazard ratio [95%CI]</td><td>p-value</td></tr><tr><td>Primary composite endpoint</td><td>793 (24.47)</td><td>937 (28.71)</td><td>0.82 [0.75; 0.90]</td><td>&lt;0.0001</td></tr><tr><td><p>Components of the composite:</p><p>- CV death<br />- Hospitalisation for worsening<br />HF</p></td><td>449 (13.85)<br />514 (15.86)</td><td>491 (15.04)<br />672 (20.59)</td><td>0.91 [0.80; 1.03]<br />0.74 [0.66; 0.83]</td><td>0.128<br />&lt;0.0001</td></tr><tr><td><p>Other secondary endpoints:</p><p>- All cause death<br />- Death from HF<br />- Hospitalisation for any cause<br />- Hospitalisation for CV reason</p></td><td>503 (15.52)<br />113 (3.49)<br />1231 (37.98)<br />977 (30.15)</td><td>552 (16.91)<br />151 (4.63)<br />1356 (41.54)<br />1122 (34.38)</td><td>0.90 [0.80; 1.02]<br />0.74 [0.58;0.94]<br />0.89 [0.82;0.96]<br />0.85 [0.78; 0.92]</td><td>0.092<br />0.014<br />0.003<br />0.0002</td></tr></tbody></table><p>The reduction in the primary endpoint was observed consistently irrespective of gender, NYHA class, ischaemic or non-ischaemic heart failure aetiology and of background history of diabetes or hypertension.<br />In the subgroup of patients with HR  75 bpm (n=4150), a greater reduction was observed in the primary composite endpoint of 24 % (hazard ratio: 0.76, 95%CI [0.68;0.85] &ndash; p&lt;0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95%CI [0.72;0.96] &ndash; p=0.0109) and CV death (hazard ratio: 0.83, 95%CI [0.71;0.97] &ndash; p=0.0166). In this subgroup of patients, the safety profile of ivabradine is in line with the one of the overall population.<br />A significant effect was observed on the primary composite endpoint in the overall group of patients receiving beta blocker therapy (hazard ratio: 0.85, 95%CI [0.76;0.94]). In the subgroup of patients with HR  75 bpm and on the recommended target dose of beta-blocker, no statistically significant benefit was observed on the primary composite endpoint (hazard ratio: 0.97, 95%CI [0.74;1.28]) and other secondary endpoints, including hospitalisation for worsening heart failure (hazard ratio: 0.79, 95% CI [0.56;1.10]) or death from heart failure (hazard ratio: 0.69, 95% CI [0.31;1.53]).<br />There was a significant improvement in NYHA class at last recorded value, 887 (28%) of patients on ivabradine improved versus 776 (24%) of patients on placebo (p=0.001).<br /><u>Paediatric population</u><br />The European Medicines Agency has deferred the obligation to submit the results of studies with Procoralan in one or more subsets of the paediatric population in the treatment of chronic heart failure (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (&gt;10 mg/ml). Ivabradine is the S-enantiomer with no bioconversion demonstrated in vivo. The Ndesmethylated derivative of ivabradine has been identified as the main active metabolite in humans.<br /><u>Absorption and bioavailability</u><br />Ivabradine is rapidly and almost completely absorbed after oral administration with a peak plasma level reached in about 1 hour under fasting condition. The absolute bioavailability of the film-coated tablets is around 40%, due to first-pass effect in the gut and liver.</p><p>Food delayed absorption by approximately 1 hour, and increased plasma exposure by 20 to 30 %. The intake of the tablet during meals is recommended in order to decrease intra-individual variability in exposure (see section 4.2).</p><p><u>Distribution</u><br />Ivabradine is approximately 70% plasma protein bound and the volume of distribution at steady-state is close to 100 l in patients. The maximum plasma concentration following chronic administration at the recommended dose of 5 mg twice daily is 22 ng/ml (CV=29%). The average plasma concentration is 10 ng/ml (CV=38%) at steady-state.<br /><u>Biotransformation</u><br />Ivabradine is extensively metabolised by the liver and the gut by oxidation through cytochrome P450 3A4 (CYP3A4) only. The major active metabolite is the N-desmethylated derivative (S 18982) with an exposure about 40% of that of the parent compound. The&nbsp; metabolism of this active metabolite also involves CYP3A4. Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations. Inversely, potent inhibitors and inducers may substantially affect ivabradine plasma concentrations (see section 4.5).<br /><u>Elimination</u><br />Ivabradine is eliminated with a main half-life of 2 hours (70-75% of the AUC) in plasma and an effective half-life of 11 hours. The total clearance is about 400 ml/min and the renal clearance is about 70 ml/min. Excretion of metabolites occurs to a similar extent via faeces and urine. About 4% of an oral dose is excreted unchanged in urine.<br /><u>Linearity/non linearity</u><br />The kinetics of ivabradine is linear over an oral dose range of 0.5 &ndash; 24 mg.<br /><u>Special populations</u><br />- Older people: no pharmacokinetic differences (AUC and Cmax) have been observed between elderly ( 65 years) or very elderly patients ( 75 years) and the overall population (see section 4.2).<br />- Renal impairment: the impact of renal impairment (creatinine clearance from 15 to 60 ml/min) on ivabradine pharmacokinetic is minimal, in relation with the low contribution of renal clearance (about 20 %) to total elimination for both ivabradine and its main metabolite S 18982 (see section 4.2).<br />- Hepatic impairment: in patients with mild hepatic impairment (Child Pugh score up to 7) unbound AUC of ivabradine and the main active metabolite were about 20% higher than in subjects with normal hepatic function. Data are insufficient to draw conclusions in patients with moderate hepatic impairment. No data are available in patients with severe hepatic impairment (see sections 4.2 and 4.3).</p><p><u>Pharmacokinetic/pharmacodynamic (PK/PD) relationship</u><br />PK/PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15-20 mg twice daily. At higher doses, the decrease in heart rate is no longer proportional to ivabradine plasma concentrations and tends to reach a plateau. High exposures to ivabradine that may occur when ivabradine is given in combination with strong CYP3A4 inhibitors may result in an excessive decrease in heart rate although this risk is reduced with moderate CYP3A4 inhibitors (see sections 4.3, 4.4 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential. Reproductive toxicity studies showed no effect of ivabradine on fertility in male and female rats. When pregnant animals were treated during organogenesis at exposures close to therapeutic doses, there was a higher incidence of foetuses with cardiac defects in the rat and a small number of foetuses with ectrodactylia in the rabbit.<br />In dogs given ivabradine (doses of 2, 7 or 24 mg/kg/day) for one year, reversible changes&nbsp; in retinal function were observed but were not associated with any damage to ocular structures. These data are&nbsp;consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisation-activated Ih currents in the retina, which share extensive homology with the cardiac pacemaker I<sub>f </sub>current.<br />Other long-term repeat dose and carcinogenicity studies revealed no clinically relevant changes.<br /><u>Environmental Risk Assessment (ERA)</u><br />The environmental risk assessment of ivabradine has been conducted in accordance to European guidelines on ERA.<br />Outcomes of these evaluations support the lack of environmental risk of ivabradine and&nbsp; ivabradine does not pose a threat to the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core<br />Lactose monohydrate<br />Magnesium stearate (E 470 B)<br />Maize starch<br />Maltodextrin<br />Silica, colloidal anhydrous (E 551)<br />Film-coating<br />Hypromellose (E 464)<br />Titanium dioxide (E171)<br />Macrogol 6000<br />Glycerol (E 422)<br />Magnesium stearate (E 470 B)<br />Yellow iron oxide (E172)<br />Red iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/PVC blister packed in cardboard boxes.<br />Pack sizes<br />Calendar packs containing 14, 28, 56, 84, 98, 100 or 112 film-coated tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier

50, rue Carnot

92284 Suresnes cedex

France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04.2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>